Eikon Therapeutics (EIKN) Company presentation summary

Pipeline overview and clinical progress

• Advancing a diverse pipeline targeting significant unmet needs in oncology and neurodegeneration, with late-stage clinical programs in melanoma, NSCLC, ovarian, breast, prostate, pancreatic, and MSI-high tumors.

• EIK1001 (TLR7/8 dual-agonist) demonstrated strong antitumor activity and tolerability in NSCLC, with high ORR and DCR in both nonsquamous and squamous cohorts; median duration of response exceeded 11 months.

• EIK1003 (PARP1 inhibitor) showed promising monotherapy and combination efficacy in ovarian and breast cancers, with manageable safety profiles and ongoing responses.

• EIK1005 (WRN inhibitor) initiated clinical trials after favorable preclinical results in MSI-high cancers, with early clinical data supporting further development.

• EIK1006 (AR antagonist) advanced as a clinical candidate for prostate cancer, with IND submission expected by end of 2026.

Technology and innovation

• Proprietary single-molecule tracking (SMT) technology enables real-time protein dynamics analysis and rapid lead optimization.

• Machine learning and computational chemistry drive AR antagonist design, improving compound prioritization and efficiency.

• Integration of advanced engineering and machine learning supports discovery and development of novel therapeutics.

Leadership and organizational strengths

• Led by a team of experienced executives and board members with backgrounds at Merck, Amgen, Moderna, JP Morgan, and other leading organizations.

• Strategic focus on leveraging internal expertise and technology platform to advance clinical-stage programs.